Moody’s assigns ‘Baa3’ rating to OU Medicine’s bonds

Moody’s Investors Service assigned its “Baa3” rating to Oklahoma City-based OU Medicine’s proposed $1 billion series 2018B and $251 million series 2018C revenue bonds.

Advertisement

The assignment is a result of several factors, including OU Medicine’s favorable market position, close ties with the University of Oklahoma, healthy cashflow margins and a strong management team that Moody’s expects will effectively lead the system through the transition to a nonprofit healthcare system.  Moody’s also acknowledged the health system’s increasingly competitive market, high leverage metrics, modest liquidity and high reliance on Medicaid and self-pay payers.

The outlook is stable, reflecting Moody’s expectation that OU Medicine will maintain strong margins during the transition period because of the tenured management team and well-planned transition strategy.

More articles on healthcare finance:
Donations to USC medical school fall 55% after dean, faculty scandals
U of Texas Health renames cancer center after donors of $25M gift
10 recent hospital, health system outlook and credit rating actions

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

Reconsider What’s Possible: Enterprise RCM and the Pro-Fee Practice

Tuesday, July 28
11:00 AM - 12:00 PM CDT

Presenters: Garett Kreitz, Med-MetrixJohn Stefanowicz, Med-Metrix

Advertisement

Next Up in Financial Management

Advertisement

Comments are closed.